Proton pump inhibitor use is associated with hip fracture development: a nationwide populationbased cohort study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Effect of proton pump inhibitor (PPI) use on the risk of hip fracture is controversial. This study aimed to clarify the association between PPI use and hip fracture risk using a large cohort. Methods: This study recruited participants from the nationwide cohort (n = 1,025,340). After exclusion of participants who had hip fractures or were aged less than 40 years during the baseline period (2002 to 2004), 371,806 participants were followed to 2013. Participants prescribed PPIs for more than 90 days during baseline period were defined as users. Fracture cases were defined when participants were hospitalized with claims of a hip fracture. Results: During 4,159,343 person-years of follow-up, fractures developed more often in PPI users than in nonusers (relative risk [RR], 1.787; 95% confidence interval [CI], 1.260 to 2.534; p = 0.002). The results persisted after adjusting for age, sex, and many drugs relevant to osteoporosis or influential in bone health. Furthermore, fracture risk associated with PPI use increased with duration of use (p trend < 0.001). The fully adjusted RRs of hip fracture development were 1.350 (95% CI, 1.203 to 1.515) for 1- to 90-day users, 1.487 (95% CI, 0.957 to 2.311) for 91- to 180-day users, and 1.771 (95% CI, 0.931 to 3.368) for > 180-day users. The positive association between PPI use and fracture was also confirmed in a subgroup with health screening data where further adjustment for body mass index, smoking status, alcohol consumption, and physical activity was available (adjusted RR, 2.025; 95% CI, 1.151 to 3.564, p = 0.014). Conclusions: PPI use is associated with hip fracture development.
Abstract
Background/Aims: Effect of proton pump inhibitor (PPI) use on the risk of hip fracture is controversial. This study aimed to clarify the association between PPI use and hip fracture risk using a large cohort. Methods: This study recruited participants from the nationwide cohort (n = 1,025,340). After exclusion of participants who had hip fractures or were aged less than 40 years during the baseline period (2002 to 2004), 371,806 participants were followed to 2013. Participants prescribed PPIs for more than 90 days during baseline period were defined as users. Fracture cases were defined when participants were hospitalized with claims of a hip fracture. Results: During 4,159,343 person-years of follow-up, fractures developed more often in PPI users than in nonusers (relative risk [RR], 1.787; 95% confidence interval [CI], 1.260 to 2.534; p = 0.002). The results persisted after adjusting for age, sex, and many drugs relevant to osteoporosis or influential in bone health. Furthermore, fracture risk associated with PPI use increased with duration of use (p trend < 0.001). The fully adjusted RRs of hip fracture development were 1.350 (95% CI, 1.203 to 1.515) for 1- to 90-day users, 1.487 (95% CI, 0.957 to 2.311) for 91- to 180-day users, and 1.771 (95% CI, 0.931 to 3.368) for > 180-day users. The positive association between PPI use and fracture was also confirmed in a subgroup with health screening data where further adjustment for body mass index, smoking status, alcohol consumption, and physical activity was available (adjusted RR, 2.025; 95% CI, 1.151 to 3.564, p = 0.014). Conclusions: PPI use is associated with hip fracture development.
참고문헌 (41)
- Targownik LE, "The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use", Am J Gastroenterol, 102, pp.942~950 (2007)
- Pottegard A, "Use of proton-pump inhibitors among adults : a Danish nationwide drug utilization study", Therap Adv Gastroenterol, 9, pp.671~678 (2016)
- Wolfe MM, "The physiology of gastric acid secretion", N Engl J Med, 319, pp.1707~1715 (1988)
- Katz PO, "Guidelines for the diagnosis and management of gastroesophageal reflux disease", Am J Gastroenterol, 108, pp.308~328 (2013)
- Poynard T, "Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer", Eur J Gastroenterol Hepatol, 7, pp.661~665 (1995)
- Dekkers CP, "Comparison of rabeprazole 20mg versus omeprazole 20 mg in the treatment of active duodenal ulcer : a European multicentre study", Aliment Pharmacol Ther, 13, pp.179~186 (1999)
- Bader JP, "Clinical efficacy of pantoprazole compared with ranitidine", Aliment Pharmacol Ther 1994;8 Suppl, 8(Suppl 1), pp.47~52 (1994)
- El-Serag HB, "Update on the epidemiology of gastro-oesophageal reflux disease : a systematic review", Gut, 63, pp.871~880 (2014)
- 정혜경, "Epidemiology of Gastroesophageal Reflux Disease in Asia: A Systematic Review", Journal of Neurogastroenterology and Motility (JNM), 17(1), pp.14~27 (2011), 대한소화기 기능성질환∙운동학회
- Valkhoff VE, "Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs)", Aliment Pharmacol Ther, 31, pp.1218~1228 (2010)
- Yang Won Min, "Recurrence and Its Impact on the Health-related Quality of Life in Patients with Gastroesophageal Reflux Disease: A Prospective Follow-up Analysis", Journal of Neurogastroenterology and Motility (JNM), 22(1), pp.86~93 (2016), 대한소화기 기능성질환∙운동학회[DOI]
- Yearsley KA, "Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea", Aliment Pharmacol Ther, 24, pp.613~619 (2006)
- Batuwitage BT, "Inappropriate prescribing of proton pump inhibitors in primary care", Postgrad Med J, 83, pp.66~68 (2007)
- Ladd AM, "Potential costs of inappropriate use of proton pump inhibitors", Am J Med Sci, 347, pp.446~451 (2014)
- Tleyjeh IM, "Association between proton pump inhibitor therapy and clostridium difficile infection : a contemporary systematic review and meta-analysis", PLoS One, 7, pp.e50836~ (2012)
- Johnstone J, "Meta-analysis : proton pump inhibitor use and the risk of community-acquired pneumonia", Aliment Pharmacol Ther, 31, pp.1165~1177 (2010)
- Yu EW, "Proton pump inhibitors and risk of fractures : a meta-analysis of 11 international studies", Am J Med, 124, pp.519~526 (2011)
- Ho PM, "Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome", JAMA, 301, pp.937~944 (2009)
- Min YW, "Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites : a propensity score matched cohort study", Aliment Pharmacol Ther, 40, pp.695~704 (2014)
- Gray SL, "Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women : results from the Women's Health Initiative", Arch Intern Med, 170, pp.765~771 (2010)
- Aseeri M, "Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients", Am J Gastroenterol, 103, pp.2308~2313 (2008)
- Laheij RJ, "Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs", JAMA, 292, pp.1955~1960 (2004)
- Yang YX, "Long-term proton pump inhibitor therapy and risk of hip fracture", JAMA, 296, pp.2947~2953 (2006)
- Corley DA, "Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients", Gastroenterology, 139, pp.93~101 (2010)
- Khalili H, "Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors : a prospective cohort study", BMJ, 344, pp.e372~ (2012)
- Fraser LA, "The effect of proton pump inhibitors on fracture risk : report from the Canadian Multicenter Osteoporosis Study", Osteoporos Int, 24, pp.1161~1168 (2013)
- Adams AL, "Proton-pump inhibitor use and hip fractures in men : a population-based case-control study", Ann Epidemiol, 24, pp.286~290 (2014)
- Cea Soriano L, "Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting", Pharmacotherapy, 34, pp.570~581 (2014)
- Lewis JR, "Long-term proton pump inhibitor therapy and falls and fractures in elderly women : a prospective cohort study", J Bone Miner Res, 29, pp.2489~2497 (2014)
- van der Hoorn MMC, "The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women : a prospective cohort study", Bone, 81, pp.675~682 (2015)
- O'Connell MB, "Effects of proton pump inhibitors on calcium carbonate absorption in women : a randomized crossover trial", Am J Med, 118, pp.778~781 (2005)
- Ensrud KE, "Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group", Ann Intern Med, 132, pp.345~353 (2000)
- Bahtiri E, "Esomeprazole use is independently associated with significant reduction of BMD : 1-year prospective comparative safety study of four proton pump inhibitors", J Bone Miner Metab, 34, pp.571~579 (2016)
- Solomon DH, "Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists : a SWAN cohort study", J Bone Miner Res, 30, pp.232~239 (2015)
- Leontiadis GI, "Proton pump inhibitors and risk of bone fractures", Curr Treat Options Gastroenterol, 12, pp.414~423 (2014)
- Lee J, "Cohort profile:the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- Targownik LE, "Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss", Gastroenterology, 138, pp.896~904 (2010)
- from the Canadian Multicentre Osteoporosis Study(CaMos), "Am J Gastroenterol", 2012, 1361~1369
- 신재무, "Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors", Journal of Neurogastroenterology and Motility (JNM), 19(1), pp.25~35 (2013), 대한소화기 기능성질환∙운동학회
- Furuta T, "CYP2C19pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor", Pharmacogenomics, 8, pp.1199~1210 (2007)
- Goldstein JA, "Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations", Pharmacogenetics, 7, pp.59~64 (1997)